TG Therapeutics (NASDAQ:TGTX) Rating Increased to Hold at StockNews.com

TG Therapeutics (NASDAQ:TGTX) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report issued on Tuesday.

A number of other equities analysts have also issued reports on the company. HC Wainwright raised their price target on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. The Goldman Sachs Group increased their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, TG Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Stock Performance

NASDAQ TGTX remained flat at $28.00 on Tuesday. The company’s stock had a trading volume of 2,930,795 shares, compared to its average volume of 2,870,394. The firm has a market capitalization of $4.36 billion, a PE ratio of -279.97 and a beta of 2.24. TG Therapeutics has a one year low of $12.84 and a one year high of $36.84. The company’s 50-day moving average is $31.30 and its 200-day moving average is $25.23. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. During the same quarter last year, the company earned $0.73 EPS. The firm’s revenue for the quarter was down 49.4% compared to the same quarter last year. On average, sell-side analysts predict that TG Therapeutics will post 0.17 earnings per share for the current year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,358 shares of company stock valued at $781,497. 10.50% of the stock is owned by company insiders.

Institutional Trading of TG Therapeutics

Several large investors have recently bought and sold shares of TGTX. Bank of New York Mellon Corp boosted its position in shares of TG Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 503,645 shares of the biopharmaceutical company’s stock worth $8,960,000 after buying an additional 59,523 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of TG Therapeutics by 32.3% in the second quarter. Principal Financial Group Inc. now owns 46,817 shares of the biopharmaceutical company’s stock valued at $833,000 after purchasing an additional 11,443 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in shares of TG Therapeutics by 1.3% during the 2nd quarter. Commonwealth Equity Services LLC now owns 186,994 shares of the biopharmaceutical company’s stock worth $3,327,000 after purchasing an additional 2,360 shares in the last quarter. Rhumbline Advisers raised its position in shares of TG Therapeutics by 7.8% during the 2nd quarter. Rhumbline Advisers now owns 215,055 shares of the biopharmaceutical company’s stock worth $3,826,000 after purchasing an additional 15,582 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in TG Therapeutics by 24.6% in the 2nd quarter. Victory Capital Management Inc. now owns 26,212 shares of the biopharmaceutical company’s stock valued at $466,000 after buying an additional 5,169 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.